Add BrightSurf on Google Email

Pusan National University researchers uncover how chronic environmental stress drives immune dysfunction in cold tumors

Researchers at Pusan National University investigated how chronic environmental stress drives immune dysfunction in cold tumors, revealing a key driver of NK-cell maladaptation: the GDF15-AhR axis. This axis sustains activation of stress-sensing receptors, gradually exhausting NK cells and enabling immune escape.

SourcePusan National University·JournalSignal Transduction and Targeted Therapy·TypeExperimental study·DateAug 18, 2026

PolyU develops AI-powered virtual patient simulation system integrating multimodal data to advance personalized cancer treatment

The PolyU developed AI Virtual Patient Simulation System combines multimodal data from genomic, medical imaging and clinical records to create a digital twin model tracking real-time changes in a patient's condition. It predicts the effectiveness of different cancer treatment options and supports personalized medical solutions.

SourceThe Hong Kong Polytechnic University·JournalMedical Image Analysis·DateAug 14, 2026

UCLA researchers receive NIH grant to boost the effectiveness of cancer immunotherapy

Researchers at UCLA Health Jonsson Comprehensive Cancer Center are developing drug-based strategies to enhance cancer immunotherapy for melanoma and potentially other cancers. They identified two promising compounds that could strengthen T cell interaction with cancer cells or make tumor cells more susceptible to destruction by T cells.

Preoperative dual immunotherapy combination shows promising activity in high-risk early-stage HER2-negative breast cancer

A phase 2 clinical trial found that combining two immunotherapies with standard chemotherapy prior to surgery improved pathologic complete response rates in high-risk, early-stage HER2-negative breast cancer patients. The regimen demonstrated strong activity among patients with ImPrint-positive tumors, including high pCR rates.

SourceGeorgetown University Medical Center·JournalJAMA Oncology·TypeRandomized controlled/clinical trial·DateJul 30, 2026

New strategy could prevent T cell exhaustion and boost immunotherapy

Researchers have identified a new strategy to prevent T cell exhaustion and boost immunotherapy by blocking MEK signaling. This approach has shown promise in lab models, enabling T cells to persist under harsh tumor conditions. However, the effectiveness of this treatment may vary among patients due to the complexity of T cell exhaustion.

SourceMemorial Sloan Kettering Cancer Center·JournalImmunity·TypeExperimental study·DateJul 23, 2026

CDI study identifies how p53 mutations drive immunotherapy resistance—and a path to overcome it

A new study reveals that p53 mutations in cancer cells can limit the effectiveness of immunotherapy by manipulating cellular metabolism, specifically through autophagy. Removing these mutant forms of p53 restores mTORC1 activity and reduces autophagy, making tumors more vulnerable to immune attack.

SourceHackensack Meridian Health·JournalCell Death and Disease·TypeExperimental study·DateJul 22, 2026

Early inflammation signal drives oral cancer development, highlights path for immunoprevention

A study published in Cancer Research identified an immune pathway that promotes the progression of oral precancerous lesions into head and neck squamous cell carcinoma. The researchers found that targeting a key inflammation signal known as interleukin-1 alpha (IL-1α) could help restore immune surveillance and prevent high-risk lesions...

Study reveals why some colorectal cancers respond better to immunotherapy

A subset of cancers, known as microsatellite instability (MSI) and deficient DNA mismatch repair (dMMR) cancers, are more visible to the immune system than others. Researchers from the Keck School of Medicine of USC identified a biological feedback loop that helps activate the immune response against these types of cancer.

SourceKeck School of Medicine of USC·JournalGastroenterology·TypeExperimental study·DateJul 16, 2026

Immune cells use previously unknown pathway to eliminate AML

Scientists at MD Anderson Cancer Center have identified a previously unknown mechanism by which T cells attack and eliminate acute myeloid leukemia (AML) cells. The discovery reveals that AML cells use a CD64-dependent pathway to evade traditional MHC recognition, potentially explaining why AML is sensitive to immune-based treatments.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalProceedings of the National Academy of Sciences·DateJul 15, 2026

Emerging roles of hepatocellular carcinoma gene signatures in prognosis and immunotherapy: challenges and opportunities

Hepatocellular carcinoma (HCC) gene signatures can predict prognosis and respond to immune checkpoint inhibitors. However, validating these signatures across different platforms and overcoming ethical concerns hinder their widespread adoption. Integrating multi-omics approaches with liquid biopsy holds promise for personalized therapy,...

SourceXia & He Publishing Inc.·JournalGene Expression·DateJul 14, 2026

Scientists develop new, improved method to find and isolate the strongest cancer-fighting immune cells

A new method called ATTACH identifies strong interactions between T cells and cancer-specific proteins to isolate effective tumor-reactive T cells. This approach overcomes key challenges in immunotherapy development, offering a rapid and accessible way for isolating rare immune cells.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalJournal for ImmunoTherapy of Cancer·DateJul 8, 2026

Radiation therapy enhances immune environment in brain metastases, improving treatment response

Researchers found that radiation therapy not only targets tumor cells but also activates immune pathways to make tumors more receptive to immunotherapy. The study suggests that radiation-immunotherapy combination strategies could improve patient outcomes by reshaping the surrounding immune landscape and recruiting T cells.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalClinical Cancer Research·DateJun 17, 2026

KRAS degradation induces rapid lung cancer regression in preclinical mouse models

Researchers discovered that degrading mutant KRAS protein leads to greater lung cancer regression and more durable antitumor responses than conventional inhibitors. The study also identifies resistance mechanisms distinct from those previously described, offering new insights into targeted protein degradation therapies.

Reusable catheters a safe choice that could save NHS millions, study finds

A new study by the University of Southampton has found that reusable catheters are just as safe for patients as single-use ones and do not increase the risk of urinary tract infections. The study followed hundreds of patients for a year and discovered that those who tested reusable catheters used 35 per cent fewer antibiotics.

SourceUniversity of Southampton·JournalInternational Journal of Nursing Studies·TypeMeta-analysis·DateMay 20, 2026

Study identifies new marker to find patients with advanced prostate cancer more likely to benefit from combination immunotherapy

Researchers discovered a new gene expression signature linked to prolonged overall survival in patients with metastatic castration-resistant prostate cancer who responded to combined immune checkpoint inhibitors. The biomarker has the potential to help identify patients most likely to benefit from this treatment combination.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalNature Communications·DateMay 20, 2026

Combination therapy with stem cell-derived immune cells boost anti-cancer response

A recent study reveals that combining iNKT cell therapy with antigen-presenting cells activated by a lipid compound triggers effective antitumor immunity. The therapy generates memory-phenotype T cells that can recognize and respond to specific threats, offering a promising personalized approach to cancer treatment.

SourceChiba University·JournalStem Cell Research & Therapy·TypeExperimental study·DateMay 7, 2026